Quarterly Earnings

All articles by Quarterly Earnings

AstraZeneca buys rights to GLP-1 drug from Eccogene for $185M upfront
AstraZeneca buys rights to GLP-1 drug from Eccogene for $185M upfront
Jack O'Brien
November 9, 2023
12:24 pm

In addition to the GLP-1 play, AstraZeneca also released its most recent earnings report Thursday morning.

Biogen ups revenue guidance, cuts earnings outlook as eyes turn to Leqembi
Biogen ups revenue guidance, cuts earnings outlook as eyes turn to Leqembi
Jack O'Brien
November 8, 2023
10:11 am

For the full-year, Biogen now expects a low-single digit percentage decline in total revenue.

Oncology, Biktarvy sales help Gilead beat Wall Street estimates
Oncology, Biktarvy sales help Gilead beat Wall Street estimates
Jack O'Brien
November 7, 2023
4:38 pm

Gilead added that it expects its full-year earnings per share to be in the range of $6.65 to $6.80.

OptimizeRx’s revenue rebounds as execs eye post-M&A profitability
OptimizeRx’s revenue rebounds as execs eye post-M&A profitability
Marc Iskowitz
November 7, 2023
5:45 am

The point-of-care messaging firm said its integration of recently acquired Medicx Health puts it on-track for ‘significant profitability and cash flow.’

BioNTech records Q3 profit, acquires liquid nanoparticle startup
BioNTech records Q3 profit, acquires liquid nanoparticle startup
Jack O'Brien
November 6, 2023
1:34 pm

BioNTech generated €895.3 million in total revenues, down from €3.4 billion in Q3 2022, while its diluted earnings per share dropped from €6.98 to €0.67 over the same period.

GLP-1 drugs carry Lilly, Novo; Moderna tops revenue expectations
GLP-1 drugs carry Lilly, Novo; Moderna tops revenue expectations
Jack O'Brien
November 2, 2023
11:13 am

In addition to Eli Lilly, Novo Nordisk and Moderna, Regeneron also produced its latest quarterly earnings report Thursday morning.

GSK’s RSV vaccine bolsters bottom line, company raises full-year guidance
GSK’s RSV vaccine bolsters bottom line, company raises full-year guidance
Jack O'Brien
November 1, 2023
10:55 am

One of the strongest segments for GSK was its vaccines division, which saw sales rise 33%. Shingrix sales increased 15% to £800 million while Arexvy sales hit £700 million.

Amgen revenue rises 4% while Pfizer posts quarterly loss
Amgen revenue rises 4% while Pfizer posts quarterly loss
Jack O'Brien
October 31, 2023
11:28 am

The decline in COVID products as the pandemic has shifted into an endemic phase was to be expected but has shown its impact on the balance sheet of major pharma companies throughout the Q3 earnings season.

Sanofi and AbbVie release Q3 earnings
Sanofi and AbbVie release Q3 earnings
Lecia Bushak
October 27, 2023
1:43 pm

Sanofi’s stock dropped after the company announced the next phase of its ‘Play to Win’ strategy, while AbbVie reported a 36% drop in Humira sales.

Takeda lowers profit guidance while Merck charges on with strong financials
Takeda lowers profit guidance while Merck charges on with strong financials
Jack O'Brien
October 26, 2023
11:19 am

Two major pharma players unveiled their most recent earnings reports and updated their respective year-end financial outlooks.

  • From Our Partners